CHRM1 and prostate cancer: Further evidence implicates parasympathetic cholinergic involvement, specifically at later stages in prostate cancer development: CHRM1 knockout mice developed primary tumors of the same size as wild-type controls, but treatment with carbachol, a muscarinic acetylcholine agonist, produced significantly more metastasis in CHRM1-positive mice.